Atlas.
Sign inStart free trial
RARENASDAQ · US

Ultragenyx Pharmaceutical Inc.

Technology · Pharmaceutical Preparations

TechnologyPharmaceutical Preparations
CEO
Emil D. Kakkis, M.D., Ph.D.
Founded
—
IPO Date
—
HQ
Novato, CA, United States
Exchange
NASDAQ
Employees
n.a.

Share Price Performance

$32.38 ▲ 37.2%
Last (1 Jul 2026) · $32
Period High · $33.39
Period Low · $18.50
52W: $18.50 – $41.44

Key Metrics

Share Price
$32.38
-3.0% today
Market Cap
$3.1B
P / E
—
EV / Revenue
4.0x
Revenue Growth
+20.2%
year-on-year
Gross Margin
—
Enterprise Value
$2.7B
52W High
$41.44
52W Low
$18.50
Avg Volume
1.9M
daily

Sources: SEC filings · Market data as of Jul 6, 2026

Shareholders' Structure
13 known institutional holders·$388M total on record·2026-Q1
BlackRock, Inc.
7.6%·$153M
State Street Corp
5.2%·$105M
Geode Capital Management, LLC
1.9%·$39M
Bank Of America Corp
1.1%·$22M
Point72 Asset Management, L.P.
0.9%·$19M
Price T Rowe Associates Inc
0.8%·$16,847
Renaissance Technologies LLC
0.6%·$12M
Northern Trust Corp
0.6%·$11M
Goldman Sachs Group Inc
0.4%·$8M
Invesco Ltd.
0.3%·$6M
Fmr LLC
0.3%·$6M
Jpmorgan Chase & Co
0.3%·$5M
Worldquant Millennium Advisors LLC
0.2%·$3M
Free Float
79.9%

Sources: SEC filings

Notes: % shown as share of total shares outstanding · Free float = shares outstanding minus all known 13F institutional holdings

What Atlas covers for Ultragenyx Pharmaceutical Inc.
OverviewUltragenyx Pharmaceutical Inc. share price history (10 years), key market statistics, and institutional shareholder structure from SEC 13F-HR filings.Business ModelHow Ultragenyx Pharmaceutical Inc. generates revenue — product and service segments, geographic breakdown, key operating metrics, and 10-year business evolution sourced from SEC filings.FinancialsUltragenyx Pharmaceutical Inc.'s complete financial history — 10 years of annual revenue, gross margins, operating income, net income, EPS, and free cash flow from SEC filings, plus 12 quarters of quarterly results.Management QualityUltragenyx Pharmaceutical Inc. executive team profiles, insider buying and selling from SEC Form 4, earnings call transcripts, and a track record of guidance delivery vs actual results.Risk FactorsUltragenyx Pharmaceutical Inc.'s annual risk disclosures from SEC filings — full text, 5-year evolution showing how risks have shifted, and year-on-year delta highlighting new and removed risks.NewsAI-synthesised news digest for Ultragenyx Pharmaceutical Inc., updated regularly with key developments, earnings updates, product announcements, and material company events.SentimentInvestor sentiment for Ultragenyx Pharmaceutical Inc. aggregated from X.com, Reddit, and Hacker News — discussion themes, Bull and Bear signals, and community analysis.Valuation & PeersUltragenyx Pharmaceutical Inc. valuation multiples — P/E, EV/Revenue, EV/EBITDA — compared against a curated set of industry peers using live data from SEC filings. Custom peer selection available.DCF BuilderBuild a discounted cash flow model for Ultragenyx Pharmaceutical Inc. with 10 years of pre-filled revenue, margins, and cash flow data from SEC filings. Adjust growth rates, WACC, and terminal assumptions.Atlas AnalysisAtlas AI research synthesis for Ultragenyx Pharmaceutical Inc. — business model, financial health, management quality, risk profile, and institutional ownership, grounded exclusively in SEC filings.

Unlock the full analysis

9-tab institutional research sourced directly from SEC filings. No tips, no scores — the same process professional investors use.

7-day free trial · Plus & Pro · No charge during trial